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 TEXT COMMENTARY 
 The EACS Philosophy and Methodology 
EACS is a non-profit organization aiming at promoting excellence in standards of care, research and 
education in HIV infection and related co-infections, and to actively engage in the formulation of public 
health policy, with the aim of reducing HIV disease burden across Europe (1).  
The overall scope of the EACS guidelines is hence to provide easy accessible recommendations to clinicians 
centrally involved with the care of HIV-positive individuals. Importantly, the guidelines are not to be 
considered as a full overview of all aspects of HIV-infection, for which we refer to more elaborate work, 
but rather as a continuously updated overview of the most relevant clinical issues in HIV. 
The EACS guidelines were first published in 2005 and are currently available in print, online at the EACS 
website (http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html) and from 2015 as a 
free App for download for iPhone and Android. The guidelines are revised annually for the electronic 
versions, and biannual for the printed version, and released during the EACS Conference. Whilst the 
guidelines are developed by European HIV-experts and initially targeted primarily at European clinicians, 
the use of the guidelines has in recent years been more widely spread, and the guidelines are therefore 
now translated into more than ten different languages (2).  
The EACS guidelines consist of five main sections including a general table overview of all major issues in 
HIV as well as more detailed recommendations on antiretroviral treatment (ART), diagnosing, 
monitoring and treatment of co-morbidities, co-infections and opportunistic diseases. Only drugs 
currently licensed by the EMA are taken into consideration in the guidelines. 
 
Each respective section (I-V) of the guidelines is managed by a Panel of experienced European HIV experts, 
and where needed additional experts, e.g. in the co-morbidity section, and governed by a three person 
Leadership Group consisting of a Panel Chair, Co-chair and Young Scientist. Furthermore, the guidelines are 
managed by a guideline Coordination Chair and Assistant from CHIP, Center for health and Infectious 
disease research, in Copenhagen Denmark working closely with the EACS secretariat in Brussels Belgium. 
Each Panel Leadership Group is responsible for the annual content revision of their section and will 
convene with other panels were there are potential overlaps in-between panels. Once all panels have 
finalised their revisions these are extensively cross-reviewed by the remaining panels and by the 
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Coordinating Chair and Assistant for consistency. A team of linguistics, translators and layout/typesetters 
then take over to produce the final version of the guidelines to be released into the public domain. 
All recommendations provided in the EACS guidelines are evidence-based whenever possible, and in the 
rare instance where adequate evidence is unavailable, based on expert opinions. A list of the main 
references used is provided as a separate section of the guidelines. All Panel members have declared their 
interest, which are available upon request. 
EACS Guidelines Version 8.0 
In the 2015 revision of the EACS guidelines (3) major revision have been made in almost all sections, the 
antiretroviral treatment (ART) section most notably have changed recommendations of when to start ART 
based on the new results of the START study (4), and the co-infection section is revised to reflect the major 
advances in anti-HCV treatment with direct-acting antivirals (DAAs) phasing out interferon (IFN)-containing 
treatment. The following paragraphs describe, in more detail, the most important changes made in each 
section of the guidelines. 
ART Section 
When to start: ART is now recommended for all HIV-positive persons, irrespectively of the CD4 count. The 
main reasons for this change in recommendation are the results from the START trial showing more 
favourable clinical outcomes among HIV-positive persons initiating ART at high CD4 counts as compared to 
persons initiating ART at lower CD4 counts (2). Along with this change the recommendations of what to 
start have also been changed in the new guideline version. 
Table 1 Recommendations for Initiation of ART in HIV-positive Persons with Chronic Infection                         
without Prior ART Exposure1 
Symptomatic HIV disease (CDC B or 
C conditions, incl. tuberculosis) 
Asymptomatic HIV infection 
 Current CD4 count 
Any CD4 count <350 
 
          <350 ≥350 
SR SR R 
SR =  Strongly Recommended   R =  Recommended                                                                                                                                                                               
1.Table modified from the EACS guidelines version 8.0 
What to start: Preferred regimens have been reduced from thirteen to six options, four Integrase-inhibitor 
(INSTI)-based, one Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based, and one ritonavir-
boosted Protease Inhibitor (PI/r)-based (Table 2). Changes are mainly based on the results of trials with 
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regimens containing INSTIs. The panel also considered that at least one regimen containing a PI/r and one 
containing a NNRTI should be listed as ‘preferred’ treatment options.  
Table 2. Initial Combination Regimen for ART-naive Adult HIV-positive Persons1 
A) Recommended Regimens (One of the following to be selected, in alphabetic order) 
Regimen Dosing Food requirement Caution 
2 NRTIs + INSTI 
ABC/3TC/DTG(i, ii) ABC/3TC/DTG 600/300/50 mg, 1 tablet qd Any time Co-administration of antacids, 
containing Al, Ca or Mg is not 
recommended. DTG 50 mg bid with 
rifampicin 
TDF/FTC(iii, iv) + DTG TDF/FTC 300/200 mg, 1 tablet qd + DTG 50 mg, 1 tablet qd Any time 
TDF/FTC/EVG/c(iii, iv) TDF/FTC/EVG/c 300/200/150/150 mg, 1 tablet  qd With food Co-administration of antacids, 
containing Al, Ca or Mg is not 
recommended 
TDF/FTC(iii, iv) + RAL TDF/FTC 300/200 mg, 1 tablet qd + RAL 400 mg, 1 tablet  bid Any time Co-administration of antacids, 
containing Al, Ca or Mg is not 
recommended. RAL 400 or 800 mg 
bid with rifampicin 
2 NRTIs + NNRTI 
TDF/FTC/RPV(iii) TDF/FTC/RPV 300/200/25 mg, 1 tablet qd With food (min 390 Kcal 
required) 
Only if CD4 count >200 cells/µL 
and HIV VL <100,000 copies/mL. 
PPI contraindicated; H2 antago- 
nists to be taken 12h before or 4h 
after RPV 
2 NRTIs + PI/r 
TDF/FTC(iii, iv) + DRV/r TDF/FTC 300/200 mg, 1 tablet qd + DRV 800 mg, 1 tablet  qd 
+ RTV 100 mg, 1 tablet qd 
With food Monitor in persons with a known 
sulfonamide allergy 
 
B) Alternative Regimens (to be used when none of the preferred regimens are feasible or available, 
whatever the reason) 
Regimen Dosing Food requirement Caution 
2 NRTIs + INSTI 
ABC/3TC(i, ii) + RAL ABC/3TC 600/300 mg, 1 tablet qd + RAL 400 mg, 1 tablet  bid Any time Co-administration of antacids, 
containing Al, Ca or Mg is not 
recommended. RAL 400 or 800 mg 
bid with rifampicin 
2 NRTIs + NNRTI 
ABC/3TC(i, ii) + EFV (vi) ABC/3TC 600/300 mg, 1 tablet qd + EFV 600 mg, 1 tablet qd At bed time or 2 hours 
before dinner 
TDF/FTC/EFV(iii, iv) TDF/FTC/EFV 300/200/600 mg, 1 tablet qd At bed time or 2 hours 
before dinner 
2 NRTIs + PI/r or PI/c 
ABC/3TC(i, ii) + ATV/r ABC/3TC 600/300 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
RTV 100 mg, 1 tablet qd 
With food  
 
Co-administration with PPI is con- 
traindicated.(vii) 
TDF/FTC(iii, iv) + ATV/r TDF/FTC 300/200 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
RTV 1 tablet 100 mg qd 
With food 
ABC/3TC(i, ii) + ATV/c ABC/3TC 600/300 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
COBI 150 mg, 1 tablet qd 
With food 
TDF/FTC(iii, iv) + ATV/c TDF/FTC 300/200 mg, 1 tablet qd + ATV 300 mg, 1 tablet qd + 
COBI 150 mg, 1 tablet qd 
With food Co-administration with PPI is con- 
traindicated.(vii) 
eGFR <70 mL/min: combination not 
recommended. 
ABC/3TC(i, ii) + DRV/r ABC/3TC 600/300 mg, 1 tablet qd + DRV 800 mg, 1 tablet  qd 
+ RTV 1 tablet 100 mg qd 
With food  
Monitor in persons with a known 
sulfonamide allergy. ABC/3TC(i, ii) + DRV/c ABC/3TC 600/300 mg, 1 tablet qd + DRV 800 mg, 1 tablet  qd 
+ COBI 150 mg, 1 tablet qd 
With food 
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TDF/FTC(iii, iv) + DRV/c TDF/FTC 300/200 mg, 1 tablet qd + DRV 800 mg, 1 tablet  qd 
+ COBI 150 mg, 1 tablet qd 
With food Monitor in persons with a known 
sulfonamide allergy. 
eGFR <70 mL/min: combination not 
recommended. 
TDF/FTC(iii, iv) + LPV/r TDF/FTC 300/200 mg, 1 tablet qd + LPV 200 mg, 2 tablets bid 
+ RTV 50 mg, 2 tablets bid 
With food Use with caution in persons with 
high cardiovascular risk 
Other combinations 
3TC(ii) + LPV/r 3TC 300 mg, 1 tablet qd + LPV 200 mg, 2 tablets bid + RTV 
50 mg, 2 tablets bid 
With food 
RAL(ii) + DRV/r RAL 400 mg, 1 tablet bid +DRV 800 mg, 1 tablet qd + RTV 
100 mg, 1 tablet qd 
With food Only if CD4 count > 200 cells/µL 
and HIV-VL < 100,000 copies/mL. 
Co-administration of antacids con- 
taining Al or Mg not recommended.  
1. Table modified from the EACS guidelines version 8.0 
i ABC contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counseling on HSR risk still mandatory. ABC should be used 
with caution in persons with a high CVD risk (>20%).  
ii Use this combination only if HBs Ag negative 
iii Avoid TDF if osteoporosis, renal monitoring required. 
iv If TDF/FTC is not available, 1 alternative could be TDF + 3TC as separate entities. 
v EVG/c/TDF/FTC: use only if eGFR ≥ 70 ml/min. It is recommended that EVG/c/TDF/FTC not be initiated in persons with eGFR < 90 mL/min 
unless this is the preferred treatment.  
vi EFV: not to be given if history of suicide attempts or mental illness; not recommended to be initiated in pregnant women or women with no 
reliable and consistent contraception; continuation is possible if EFV is already started before pregnancy; not active against HIV-2 and HIV-
1 group O strains. 
vii  If PPI co-administration is judged unavoidable, consider an alternative regimen; if given, dose increase of ATV to 400 mg qd may be 
considered, close clinical monitoring is recommended and doses of PPI comparable to omeprazole 20 mg should not be exceeded and 
must be taken approximately 12 hours prior to the ATV/r. H2 antagonists to be taken 12h before or 4h after ATV. 
 
Post-exposure prophylaxis (PEP): Based on the results of the PARTNER Study, the recommendations on PEP 
for sexual exposure to HIV were revised to reflect that if an HIV-positive source person has documented 
undetectable plasma HIV-RNA, PEP is no longer recommended. Uses of tenofovir/emtricitabine + 
raltegravir or boosted-darunavir are now also recommended as ARV regimens for PEP. 
Pre-exposure prophylaxis (PrEP): A brand new section on PrEP has been added to the guidelines. PrEP 
(TDF/FTC) should be recommended to high-risk men who have sex with men (MSM) and transgender 
individuals and considered for high-risk heterosexual men and women. Both continuous and ‘on demand’ 
options are discussed as possible approaches. 
Co-morbidity section 
Ageing and co-morbidities; A highlight was added on the growing proportion of HIV-positive individuals 
with advanced age and multiple simultaneous co-morbidities, that may benefit the most from a 
multidisciplinary assessment. As such, intensified monitoring of renal function was recommended in 
individuals with an estimated glomerular filtration rate (eGFR) < 90 mL/min and with progressively 
declining eGFR. The use of a chronic kidney disease risk equations is also recommended.  Furthermore, 
screening for depression is now encouraged more widely due to the high prevalence, recommendations for 
smoking cessation were further elaborated and recommendations for regular assessment of liver disease in 
individuals with viral hepatitis co-infection with ultrasound and fibrosis staging were added. 
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New drugs /drug combinations;  A number of new antiretroviral drugs/drug combinations were included in 
the revised tables on drug-drug interaction, adverse effect, dose adjustment for renal/liver insufficiency  
and in the table for administration of ART in individuals with swallowing difficulties. Several of these tables 
have, in previous version of the EACS guidelines, been available exclusively in the electronic version, 
however due to requests from the guideline users the tables on dose adjustment for renal/liver 
insufficiency and administration of ART in individuals with swallowing difficulties are now also available in 
the print version.  
Drug-drug interactions; Two new drug-drug interaction tables have been included in the 2015 guidelines on 
interactions with corticosteroids and contraceptive drugs with use of ART. 
Cardiovascular diseases (CVD) risk factors; In the general population several guidelines on risk factors (i.e. 
dyslipidemia) for CVD have ceased to use threshold values. However the Co-morbidity Panel have in the 
revised version kept threshold values for all CVD risk factors to aid everyday clinical practise.  
Vaccination: A general recommendation to avoid polysaccharide vaccination was added, as was a 
recommendation of influenza and streptococcus pneumonia vaccination in all HIV-positive persons. 
Co-infections 
Treatment of HBV: the guideline text and tables now reflect the general recommendation to start ART in 
the presence of HBV co-infection regardless of the CD4 count. ART should contain tenofovir as a dually 
active agent against HIV and HBV infection. 
Treatment of chronic HCV: Analogous to HBV guideline text and tables now also reflect the general 
recommendation to start ART in the presence of HCV co-infection regardless of the CD4 count. A stronger 
emphasis is put on IFN-free treatment regimens (Table 3) as well as earlier start of DAA treatment in cases 
where there is risk of liver disease progression. As such, all detailed recommendations on IFN-containing 
regimens have been removed from the main HCV treatment section. Acknowledging that IFN-containing 
treatment is still being used in certain countries, recommendations on IFN-containing treatment have been 
collected in an addendum available online. Text and tables have furthermore been updated following the 
licensing of sofosbuvir/ledipasvir and AbbVie 3D combo. The drug-drug interaction table of DAAs and ARVs 
has subsequently also been updated.  
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Table 3. HCV Treatment Options in HCV/HIV Co-infected Persons1 
IFN-free HCV Treatment Options 
 
HCV GT 
 
Treatment regimen 
Treatment duration & ribavirin usage 
Non-cirrhotic Compensated 
cirrhotic 
Decompensated 
cirrhotics CTP 
class B/C 
1 & 4 SOF + SMP + RBV 12 weeks without RBV 12 weeks with RBV 
or 24 weeks without 
RBV(i) 
Not recommended 
SOF/LDV + RBV 12 weeks without RBV 12 weeks with RBV or 24 weeks without 
RBV in cirrhotics or pre-/post-transplant(i) 
SOF + DCV + RBV 12 weeks without RBV 12 weeks with RBV or 24 weeks without 
RBV in cirrhotics or pre-/post-transplant(i) 
OBV/PTV/r + DSV 12 weeks in GT 1b Not Recommended 
OBV/PTV/r + DSV + RBV 12 weeks in GT 1a 12 weeks in GT 1b 
24 weeks in GT 1a 
Not recommended 
OBV/PTV/r + RBV 12 weeks in GT 4 24 weeks in GT 4 Not recommended 
2 SOF + DCV + RBV 12 weeks without RBV 12 weeks without RBV  12 weeks with RBV 
SOF + RBV 12 weeks 16-20 weeks(ii) 
3 SOF + PEG-IFN/RBV Not recommended 12 weeks in persons 
eligible for PEG-IFN 
Not recommended 
SOF + RBV 24 weeks Not recommended 
SOF + DCV + RBV(iii) 12 weeks without RBV 24 weeks with RBV 
5 SOF/LDV 12 weeks without RBV 12 weeks without RBV 
6 In the absence of clinical data on DAAs in HCV GT 6 infection 
persons should be treated similarly to HCV GT 1 and 4 infection 
1. Table modified from the EACS guidelines version 8.0 
RBV =  Ribavirin                                                                                                                                                                                                                        
SOF =  Sofosbuvir                                                                                                                                                                 
SMP =  Simeprevir                                                                                                                                                                   
DCV =  Daclatasvir                                                                                                                                                                           
LDV =   Ledipasvir                                                                                                                                                                   
OBV =  Ombitasvir                                                                                                                                                                                      
PTV/r = Paritaprevir/Ritonavir                                                                                                                                                        
DSV  = Dasabuvir                                                                                                                                                                                                                 
IFN= Interferon                                                                                                                                                                                                                                       
i Cirrhotic persons with negative predictors of response can be treated 24 weeks with RBV (negative predictors: treatment-experienced, platelet 
count <75x103 cells/uL)                                                                                                                                                                                                   
ii Possible extension up to 16 weeks in treatment-naïve cirrhotics or relapsers; up to 20 weeks in treatment-experienced cirrhotics                                         
iii Based on expert opinion and preliminary data from studies in persons on pre-marketing expanded access programs 
Treatment of acute HCV: In the absence of randomized, controlled data on the use of DAAs in the setting of 
acute HCV co-infection treatment with pegylated-IFN and ribavirin should be based on an individual 
decision weighing the known toxicities and long treatment duration against a potentially strong patient 
wish for early HCV cure particularly in HIV-positive MSM with a higher risk of HCV transmission and in 
countries where DAAs will only be reimbursed in chronic HCV with advanced fibrosis. 
Opportunistic diseases 
Whilst the overall content of this section has not undergone major changes, the structure has changed 
considerably. In previous versions of the guidelines, the recommendations for opportunistic diseases were 
subdivided into three overview tables on primary prophylaxis, treatment and secondary 
prophylaxis/maintenance treatment. In the 2015 version, the recommendations are now structured 
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according to the individual pathogens/diseases to ease the overview. Newly, each section contents a short 
abstract on diagnostics for each opportunistic disease.  Additionally, a new overview table on CD4 count 
thresholds as indication for different primary prophylaxes has been added. The section on Cryptococcosis  
was complemented by a recommendation for pre-emptive treatment. 
New tables: Entirely new tables with recommendations on treatment of Progressive Multifocal 
Leukoencephalopathy (PML), Histoplasmosis, Cryptosporidiosis and Cystoisosporiasis were added.  
Conclusion 
The diagnosis and management of HIV infection and related co-infections, opportunistic diseases and co-
morbidities continue to require a multidisciplinary effort for which the 2015 version of the EACS guidelines 
provides an easy assessable and updated overview.  
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